Reduction of Cholesterol and Lipids in Man by Ethyl p-Chlorophenoxyisobutyrate
Authors: LEON HELLMAN
Journal: Annals of Internal Medicine (1963)

Article1 October 1963Reduction of Cholesterol and Lipids in Man by Ethyl p-ChlorophenoxyisobutyrateLEON HELLMAN, M.D., F.A.C.P., BARNETT ZUMOFF, M.D., GERALD KESSLER, PH.D., ELMER KARA, M.D., IRA L. RUBIN, M.D., F.A.C.P., ROBERT S. ROSENFELD, PH.D.LEON HELLMAN, M.D., F.A.C.P., BARNETT ZUMOFF, M.D., GERALD KESSLER, PH.D., ELMER KARA, M.D., IRA L. RUBIN, M.D., F.A.C.P., ROBERT S. ROSENFELD, PH.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-4-477 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThorp and Waring (1) studied a series of aryloxyisobutyric acids in rats for their ability to lower the level of cholesterol and lipids in serum and liver and found the compounds with maximum activity and minimum toxicity to be p-chlorophenoxyisobutyric acid (CPIB) or its ethyl ester, clofibrate (ethyl p-chlorophenoxyisobutyric acid) (CPIB ester). Because the cholesterol-lowering activity of CPIB ester (Figure 1) in treated rats appeared to coincide in time with spontaneous reductions in the serum cholesterol of control rats, the hypothesis was developed that CPIB ester augmented a rhythmic endogenous hypocholesteremic mechanism. Evidence was adduced that increases in adrenal cortical...References1. THORPWARING JMWS: Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate. Nature 194: 948, 1962. CrossrefMedlineGoogle Scholar2. BERNSTEIN JG: The effect of thermal environment on the morphology of the thyroid and adrenal cortical glands in the albino rat. Endocrinology 28: 985, 1941. CrossrefGoogle Scholar3. HELLMANBRADLOWZUMOFFFUKUSHIMAGALLAGHER LHBDKTF: Thyroid-androgen interrelations and the hypocholesteremic effect of androsterone. J. Clin. Endocr. XIX: 936, 1959. CrossrefGoogle Scholar4. OLIVER MF: Reduction of serum-lipid and uric-acid levels by an orally active androsterone. Lancet 1321, 1962. CrossrefMedlineGoogle Scholar5. HELLMANZUMOFFKESSLERROSENFELDGALLAGHER LBGRTF: Reduction of serum cholesterol in man by an oral androsterone preparation. J. Clin. Invest. 41: 1364, 1962. Google Scholar6. COHENHIGANOROBINSONLE BEAU WDNRWRJ: Changes in serum lipids and urinary ketosteroids during oral and intramuscular administration of androsterone. J. Clin. Endocr. XXI: 1208, 1961. CrossrefGoogle Scholar7. SCHOENHEIMERSPERRY RWM: A micromethod for the determination of free and combined cholesterol. J. Biol. Chem. 106: 745, 1934. CrossrefGoogle Scholar8. HAWKOSERSUMMERSON PBBLWH: Practical Physiological Chemistry, 13th ed., McGraw-Hill Book Co. Inc., New York, 1954, p. 589. Google Scholar9. SPERRYBRAND WMFC: The determination of total lipids in blood serum. J. Biol. Chem. 213: 69, 1955. CrossrefMedlineGoogle Scholar10. VAN HANDELZILVERSMIT EDB: Micromethod for the direct determination of serum triglycerides. J. Lab. Clin. Med. 50: 152, 1957. MedlineGoogle Scholar11. CARLSONWADSTROM LALB: Determination of glycerides in blood serum. Clin. Chim. Acta 4: 197, 1959. CrossrefMedlineGoogle Scholar12. AVIGANSTEINBERGVROMANTHOMPSONMOSETTIG JDHEMJE: Studies of cholesterol biosynthesis. I. The identification of desmosterol in serum and tissues of animals and man treated with MER-29. J. Biol. Chem. 235: 3123, 1960. CrossrefMedlineGoogle Scholar13. ABELLLEVYBRODIEKENDALL LLBBBBFE: A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J. Biol. Chem. 195: 357, 1952. CrossrefMedlineGoogle Scholar14. STEINBERGAVIGANFEIGELSON DJEB: Effects of triparanol (MER-29) on cholesterol biosynthesis and on blood sterol levels in man. J. Clin. Invest. 40: 884, 1961. CrossrefMedlineGoogle Scholar15. BESSEYLOWRYBROCK OAOHMJ: A method for the rapid determination of alkaline phosphatase with five cubic millimeters of serum. J. Biol. Chem. 164: 321, 1946. CrossrefMedlineGoogle Scholar16. REITMANFRANKEL SS: A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Amer. J. Clin. Path. 28: 56, 1957. CrossrefMedlineGoogle Scholar17. Uric Acid Methodology Notes (3-60): Technicon Instruments Corp., Chauncey, New York. Google Scholar18. HAWKOSERSUMMERSON PBBLWH: Practical Physiological Chemistry, 13th ed., McGraw-Hill Book Co. Inc., New York, 1954, p. 597. Google Scholar19. Glucose Methodology Notes (2-59): Technicon Instruments Corp., Chauncey, New York. Google Scholar20. OLIVERROBERTSHAYESPANTRIDGESUZMANBERSOHN MFSDDJFMMI: Effect of atromid and ethyl chlorophenoxyisobutyrate on anticoagulant requirements. Lancet. 143, 1963. CrossrefMedlineGoogle Scholar21. DENSON KW: The specific assay of Prower-Stuart factor and factor VII. Acta Haemat. (Basel) 25: 105, 1961. CrossrefMedlineGoogle Scholar22. SPAETCINTRON THJ: Pathways to blood coagulation product. I. Formation. Blood (in press). Google Scholar23. GALIMBERTIDEFRANCESCHI PA: Synthesis of some α-derivatives of isobutyric acid. Gazz. Chem. Ital. 77: 431, 1947. Google Scholar24. JULIABAILLARGETSCHERNOFF MMG: Sur quelques nouveaux derivés aryloxyisobutyriques et apparentés. Bull. Soc. Chim. France 776, 1956. Google Scholar25. STEINBERGFREDRICKSON DDS: Inhibition of lipid synthesis by alpha-phenyl-n-butyrate and related compounds. Proc. Soc. Exp. Biol. Med. 90: 232, 1955. CrossrefMedlineGoogle Scholar26. FREDRICKSONSTEINBERG DSD: Failure of alpha-phenylbutyrate and beta-phenylvalerate in treatment of hypercholesterolemia. Circulation 15: 391, 1957. CrossrefMedlineGoogle Scholar27. COTTETMATHIVATREDEL JAJ: Etude thérapeutique d'un hypocholesterolémiant de synthèse: l'acide phényl-éthyl-acetique. Presse Med. 62: 939, 1954. MedlineGoogle Scholar28. HUFFGILFILLAN JWL: Benzmalecene: Inhibition of cholesterol biosynthesis and hypocholesteremic effect in rats. Proc. Soc. Exp. Biol. Med. 103: 41, 1960. CrossrefMedlineGoogle Scholar29. BERGENVAN ITALLIESEBRELL SSTBWH: Hypocholesteremic effect in man of benzmalecene: An inhibitor of cholesterol biosynthesis. Proc. Soc. Exp. Biol. Med. 103: 39, 1960. CrossrefMedlineGoogle Scholar30. SACHSDANIELSONSPERBER BAERJ: Hypocholesterolemic effects of N- (1-methyl-2, 3-di-p-chlorophenylpropyl)-maleamic acid in hyperlipemic and normolipemic man. Metabolism 9: 783, 1960. MedlineGoogle Scholar31. ACHORWINKELMANNPERRY RWRKHO: Cutaneous side-effects from use of triparanol (MER-29): Preliminary data on ichthyosis and loss of hair. Proc. Mayo Clin. 36: 217, 1961. MedlineGoogle Scholar32. LAUGHLINCAREY RCTF: Cataracts in patients treated with triparanol. JAMA 181: 339, 1962. CrossrefMedlineGoogle Scholar33. GERTLERWHITE MMPD: Coronary Heart Disease in Young Adults, Harvard University Press, Cambridge, Massachusetts, 1954, p. 120. Google Scholar34. ALBRINKMEIGSMAN MJWJEB: Serum lipids, hypertension and coronary artery disease. Amer. J. Med. XXXI: 4, 1961. CrossrefGoogle Scholar35. BEVANSDAVIDSONKENDALL MJDFE: Regression of lesions in canine arteriosclerosis. Arch. Path. (Chicago) 51: 288, 1951. MedlineGoogle Scholar36. STROMJENSEN ARA: Mortality from circulatory diseases in Norway 1940-1945. Lancet 1: 126, 1951. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, New YorkFrom the Division of Neoplastic Medicine, Montefiore Hospital and the Division of Steroid Biochemistry and Metabolism, Sloan-Kettering Institute for Cancer Research, New York, N. Y.This work was supported in part by grants HE-06992, FR-53, and CA-03207 from the National Institutes of Health, United States Public Health Service, Bethesda, Maryland.A preliminary report of these findings was presented in June, 1962 at a meeting held at Imperial Chemical Industries, Ltd., Alderley Park, England.Requests for reprints should be addressed to Leon Hellman, M.D., Montefiore Hospital, 210th St. and Bainbridge Ave., New York 67, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByThe Role of Fibrates in Primary Biliary CholangitisFibrates: Risk Benefits and Role in Treating DyslipidemiasThe Search for Cholesterol-lowering DrugsPatent Evaluation: Phenoxyalkanoic Acids as Cholesterol Lowering AgentsEffect of clofibrate on cholesterol metabolism in rats treated with polychlorinated biphenylsComparative hypolipidemic effects of clofibric acid and itanoxone on the metabolism and the distribution of lipids in the crab Pachygrapsus marmora tus (Decapoda, Brachyura)Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: Colestipol and clofibrateEffects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of ratsThe concentration of high density lipoprotein in patients with type IV hyperlipoproteinemia and the effect of clofibrateBiogenesis of Peroxisomes and GlyoxysomesSelective effects of clofibrate on alkaline phosphatase isoenzymes in serumDrug management of hypercholesterolemiaFATTY ACID COMPOSITION OF CHOLESTERYL ESTERS IN CHOLESTEROL-FED RABBITS TREATED WITHLIPID-LOWERING AGENT (ETHYL 2-(p-CHLOROPHENOXY) ISOBUTYRATE)*Clofibrate retardation of naturally-occurring arteriosclerosis in repeatedly-bred male and female ratsMedikament�se Behandlung prim�rer Hyperlipoprotein�mienEffect of Clofibrate on Plasma Levels of Alkaline PhosphataseThree Hypolipidemic Drugs Increase Hepatic Palmitoyl-Coenzyme A Oxidation in the RatReduced activity of hepatic microsomal fatty acid chain elongation synthesis in clofibrate-fed ratsEffect of ethyl p-chlorophenoxyisobutyrate on the adrenocortical glucocorticoid function in guinea pigsReduction of Serum Alkaline Phosphatase and Gamma-Glutamyl Transpeptidase Activities by Short-Term ClofibrateClofibrate in Type II HyperlipoproteinemiaDrug DistributionDose-response effect of single and combined clofibrate (Atromidin®) and niceritrol (perycit®) treatment on serum lipids and lipoproteins in type II hyperlipoproteinaemiaImpotence in patients treated with clofibrateFETAL VIABILITYREDUCTION OF SERUM-ALKALINE- PHOSPHATASE BY CLOFIBRATE4 Antihyperlipidaemic AgentsEffect of al-chlorophenoxyisobutyrate (alufibrate) on pyruvate metabolism and on the fate of very low density lipoprotein lipids in hyperlipidemic patientsThe activity of the different carnitine acyltransferases in the liver of clofibrate-fed ratsEffect in vitro of clofibrate and trans-l,4-bis-(2-chlorobenzylaminoethyl)-cyclohexane dihydrochloride (AY 9944) on respiration and adenosine triphosphatase activity of mouse liver mitochondriaThe effect of clofibrate on serum and faecal lipidsDrug Interactions with Coumarin AnticoagulantsEffects of chlorophenoxyisobutyrate on the synthesis and metabolism of cholesterol in manEffect of chlorophenoxyisobutyrate on the metabolism of endogenous glycerides in manEffect of clofibrate on plasma lipids of rat and rabbitMode of action of lipid-lowering agents. II. In vitro inhibition of acetyl coenzyme A carboxylase by a hypolipidemic drugEffect of clofibrate (ethyl-chlorophenoxyisobutyrate) feeding on glycolytic and lipogenic enzymes and hepatic glycogen synthesis in the ratReduction of Serum Cholesterol and Triglyceride Levels by the Combined Administration of Neomycin and ClofibrateParadoxical Elevation of Serum Cholesterol by Clofibrate in Patients with Primary Biliary CirrhosisInhibition of Hepatic Acetyl Coenzyme A Carboxylase by Hypolipidemic AgentsThe effect of clofibrate on the serum triglyceride concentration in normal males fed high-sucrose dietsLong-Term Effects of Clofibrate (Atromid-S) on Serum Lipids in ManClofibrate-Induced Changes in the Activity of Human Intestinal EnzymesHypolipidemic AgentsMeasures to Reduce the Serum Lipid Levels in Coronary Heart DiseaseAppraisal of clofibrate as a hypolipidemic agentSome clinical potentials of chlorophenoxyisobutyrate (clofibrate) therapy (hyperlipidemia-angina pectoris-blood sludging-diabetic neuropathy)Dietary and Other Factors Which Influence Serum LipidsThe effects of clofibrate on the metabolism of C14 labeled tripalmitin in the human subjectThe mechanisms underlying the hypolipidaemic effects of atromid S, nicotinic acid and benzmalecene—IEssential HypercholesterolemiaEssential HyperlipemiaThe long-term effects of atromid on serum cholesterolTRIAL OF "ATHERAN" AND "ATROMID‐S" IN ATHEROSCLEROSISSURFACE UPTAKE OF THE AZO DYE LUXOL ARN BY HUMAN PLATELETSDynamics of plasma triglyceride turnover in manStudies with ethyl chlorophenoxyisobutyrate (clofibrate)The effects of chlorophenoxyisobutyrate with and without androsterone on the serum lipids, fat tolerance, and uric acidReduction of serum triglycerides and cholesterol by ethyl p-chlorophenoxyisobutyrate (CPIB)THE TREATMENT OF XANTHOMATOSIS WITH "ATROMID"Drugs affecting lipid synthesisTherapy of hypercholesterolemia 1 October 1963Volume 59, Issue 4Page: 477-494KeywordsAcidsAtherosclerosisBiochemistryCholesterolHospital medicineLipidsLiverMedical servicesPrevention, policy, and public healthToxicity Issue Published: 1 October 1963 PDF DownloadLoading ...